EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1

Xingkang Wu iD, Yang Li, Chenchen Han, Shifei Li iD, Xuemei Qin

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25179226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Xingkang Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Modern Research Center for Traditional Chinese Medicine, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanx…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Isocitrate Dehydrogenase, Bile Duct Neoplasms, Piperidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanxi Key Laboratory of Redevelopment of Famous Local Traditional Chinese Medicines, Natural Science Funding of Shanxi Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intrahepatic cholangiocarcinoma (ICC) is a universally lethal malignancy with increasing incidence. However, ICC patients receive limited benefits from current drugs; therefore, we must urgently explore new drugs for treating ICC. Quinolizidine alkaloids, as essential active ingredients extracted from Sophora alopecuroides Linn, can suppress cancer cell growth via numerous mechanisms and have therapeutic effects on liver-related diseases. However, the impact of quinolizidine alkaloids on intrahepatic cholangiocarcinoma has not been fully studied. In this article, the in vitro anti-ICC activities of six natural quinolizidine alkaloids were explored. Aloperine was the most potent antitumor compound among the tested quinolizidine alkaloids, and it preferentially inhibited RBE cells rather than HCCC-9810 cells. Mechanistically, aloperine can potentially decrease glutamate content by inhibiting the hydrolysis of glutamine, reducing D-2-hydroxyglutarate levels and, consequently, leading to preferential growth inhibition in isocitrate dehydrogenase (IDH)-mutant ICC cells. In addition, aloperine preferentially resensitizes RBE cells to 5-fluorouracil, AGI-5198 and olaparib. This article demonstrates that aloperine shows preferential antitumor effects in intrahepatic cholangiocarcinoma cells harboring the mutant IDH1 by decreasing D-2-hydroxyglutarate, suggesting that aloperine could be used as a lead compound or adjuvant chemotherapy drug to treat ICC harboring the mutant IDH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaIsocitrate DehydrogenaseBile Duct NeoplasmsPiperidinesAntineoplastic AgentsMutationHumansCell Line, TumorQuinolizidinesCell Proliferation

Stichwörter der Autor:innen

D-2-hydroxyglutarateIDH mutationaloperineintrahepatic cholangiocarcinomaquinolizidine alkaloids

Substanzen

Isocitrate DehydrogenasePiperidinesAntineoplastic AgentsaloperineQuinolizidinesIDH1 protein, human

Autor:innen und Institutionen

  • Modern Research Center for Traditional Chinese Medicine, Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Shanxi University, No. 92, Wucheng Road, Taiyuan 030006, China.
  • Key Laboratory of Chemical Biology and Molecular Engineering of Education Ministry, Institute of Molecular Science, Shanxi University, No. 92, Wucheng Road, Taiyuan 030006, China.

ORCID-Profile: Xingkang Wu, Shifei Li

Förderung

  • Shanxi Key Laboratory of Redevelopment of Famous Local Traditional Chinese Medicines
  • Natural Science Funding of Shanxi Province
  • National Natural Science Foundation of China
  • the Program of State Key Laboratory of Quantum Optics and Quantum Optics Devices
  • the Traditional Chinese Medicine Innovation Team of Shanxi Province
  • the Innovation Team of Shandong Higher School Youth Innovation Technology Program
  • Shanxi Key Laboratory of Redevelopment of Famous Local Traditional Chinese Medicines, Shanxi University

Zitieren

APA

Wu, X., Li, Y., Han, C., Li, S., & Qin, X. (2024). Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179226

Vancouver

Wu X, Li Y, Han C, Li S, Qin X. Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179226

BibTeX
@article{Wu2024,
  author = {Wu, Xingkang and Li, Yang and Han, Chenchen and Li, Shifei and Qin, Xuemei},
  title = {Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179226}
}
Kostenlos starten →